With more and more gene therapies advancing into clinical testing, the FDA has paid close attention to signs of safety risks, issuing orders to stop testing in a number of recent cases involving developers like UniQure, Bluebird bio, Pfizer and Astellas Pharma.
Some of those, such as for UniQure and Bluebird, were later resolved after companies produced evidence showing their treatments were unlikely to be the principal cause.
